Unrelated HSCT in Patients With Fanconi Anemia

Status Withdrawn

Clinical Trial Summary

The protocol is designed for the compassionate treatment of patients with Fanconi Anemia who do not have an HLA-matched sibling donor. The purpose of this study is to determine the likelihood of engraftment in Fanconi Anemia patients using total body irradiation (TBI), cyclophosphamide (CY), fludarabine (FLU) and antithymocyte globulin (ATG) followed by an unrelated donor hematopoietic cell transplant with T-cell depletion using the CliniMACS device.

Clinical Trial Description

The major obstacle to successful alternate donor HCT for patients with Fanconi Anemia is graft failure. While T-cell depletion decreases the incidence of aGVHD, its effect on improving long term survival is unproven. To potentially improve engraftment rate, we have chosen a relatively new immunosuppressive agent, fludarabine (FLU), FLU is an antineoplastic agent that has been shown to be an effective immunosuppressive agen in BMT conditioning therapy. The addition of FLU to the commonly used preparative regimen of CY and TBU in Fanconi Anemia patients may improve engraftment rates.

Based on all presented data and its outcome, hematopoietic stem cell transplantation with the use of total body irradiation (450 cGy), cyclophosphamide (10 mg/kg IV) and fludarabine (35 mg/m2 IV) as preparative cytoreductive therapy has become the standard treatment for the hematologic manifestations of Fanconi Anemia at CHLA. However, the use of Isolex 300i will be replaced by CliniMACS in processing T-cell depletion.

The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated. Based on the gathered data, CliniMACS has not been a contributing factor in the toxicity of patients, although may have a potential of eliciting "antibody" reactions in some patients, the process has been of significant life-saving benefit as compared to the potential risks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02127905
Study type	Interventional
Source	Children's Hospital Los Angeles
Contact
Status	Withdrawn
Phase	N/A
Start date	March 2011
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02931071` - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1	Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00084695` - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT01146210` - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	N/A
Completed	`NCT01082133` - Multicenter Transplant Study for Fanconi Anemia	Phase 2
Completed	`NCT00965666` - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia	Early Phase 1
Terminated	`NCT00290628` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A
Recruiting	`NCT00027274` - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated	`NCT01001598` - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita	Phase 1/Phase 2
Recruiting	`NCT03206086` - Eltrombopag for People With Fanconi Anemia	Phase 2
Recruiting	`NCT03579875` - T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia	Phase 2
Recruiting	`NCT05598515` - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia	N/A
Active, not recruiting	`NCT03476330` - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia	Phase 2
Terminated	`NCT05910853` - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed	`NCT03609840` - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT00479115` - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	Phase 1/Phase 2
Completed	`NCT00352976` - TBI Dose De-escalation for Fanconi Anemia	Phase 2/Phase 3
Terminated	`NCT03600909` - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.